Estrogen increases coagulation factor V mRNA levels via both estrogen receptor-α and -β in murine bone marrow/bone

European Journal of Endocrinology

Volumn 151, Issue 2, 2004, Pages 259-263

  Movérare, Sofia ^b   Skrtic, Stanko ^b   Lindberg, Marie K ^b   Dahlman Wright, Karin ^a   Ohlsson, Claes ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; CONTRACEPTIVE AGENT; ESTRADIOL BENZOATE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; BONE; BONE MARROW; CONTROLLED STUDY; DNA MICROARRAY; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; GENE EXPRESSION; GENE TARGETING; HORMONE SUBSTITUTION; LIVER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARIECTOMY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

ANIMALS; BLOOD COAGULATION; BONE MARROW; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FACTOR V; FEMALE; GENE EXPRESSION; LIVER; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, ESTROGEN; RNA, MESSENGER;

EID: 4544226111     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1510259     Document Type: Article

References (22)

1. Seligsohn U & Lubetsky A. Genetic susceptibility to venous thrombosis. New England Journal of Medicine 2001 344 1222-1231.
2. Rosendaal FR, Helmerhorst FM & Vandenbroucke JP. Female hormones and thrombosis. Arteriosclerosis, Thrombosis and Vascular Biology 2002 22 201-210.
3. Hellgren M, Svensson PJ & Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. American Journal of Obstetrics and Gynecology 1995 173 210-213.
4. Kluft C & Lansink M. Effect of oral contraceptives on haemostasis variables. Thrombosis and Haemostasis 1997 78 315-326.
5. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M & Cannon RO 3rd. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. New England Journal of Medicine 1997 336 683-690.
6. Cano A & Van Baal WM. The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas 2001 40 17-38.
7. Lindberg MK, Alatalo SL, Halleen JM, Mohan S, Gustafsson J-Å & Ohlsson C. Estrogen receptor specificity in the regulation of the skeleton in female mice. Journal of Endocrinology 2001 171 229-236.
8. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson J-Å & Smithies O. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. PNAS 1998 95 15677-15682.
9. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS & Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. PNAS 1993 90 11162-11166.
10. Vidal O, Lindberg MK, Hollberg K, Baylink DJ, Andersson G, Lubahn DB, Mohan S, Gustafsson J-Å & Ohlsson C. Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. PNAS 2000 97 5474-5479.
11. Lindberg MK, Moverare S, Eriksson A-L, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson J-Å & Ohlsson C. Identification of estrogen-regulated genes of potential importance for the regulation of trabecular bone mineral density. Journal of Bone and Mineral Research 2002 17 2183-2195.
12. Chomczynski P & Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 1987 162 156-159.
13. Yamashita T, Hashimoto S, Kaneko S, Nagai S, Toyoda N, Suzuki T, Kobayashi K & Matsushima K. Comprehensive gene expression profile of a normal human liver. Biochemical and Biophysical Research Communications 2000 269 110-116.
14. Kawamoto S, Matsumoto Y, Mizuno K, Okubo K & Matsubara K. Expression profiles of active genes in human and mouse livers. Gene 1996 174 151-158.
15. Sun H, Yang TL, Yang A, Wang X & Ginsburg D. The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis. Blood 2003 102 2856-2861.
16. Gewirtz AM, Keefer M, Doshi K, Annamalai AE, Chiu HC & Colman RW. Biology of human megakaryocyte factor V. Blood 1986 67 1639-1648.
17. Chiu HC, Schick PK & Colman RW. Biosynthesis of factor V in isolated guinea pig megakaryocytes. Journal of Clinical Investigation 1985 75 339-346.
18. Yang TL, Pipe SW, Yang A & Ginsburg D. Biosynthetic origin and functional significance of murine platelet factor V. Blood 2003 102 2851-2855.
19. Kato S, Tora L, Yamauchi J, Masushige S, Bellard M & Chambon P. A far upstream estrogen response element of the ovalbumin gene contains several half-palindromic 5′-TGACC-3′ motifs acting synergistically. Cell 1992 68 731-742.
20. Wilson DB, Salem HH, Mruk JS, Maruyama I & Majerus PW. Biosynthesis of coagulation factor V by a human hepatocellular carcinoma cell line. Journal of Clinical Investigation 1984 73 654-658.
21. Mazzorana M, Baffet G, Kneip B, Launois B & Guguen-Guillouzo C. Expression of coagulation factor V gene by normal adult human hepatocytes in primary culture. British Journal of Haematology 1991 78 229-235.
22. Dahlback B, Carlsson M & Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. PNAS 1993 90 1004-1008.